康希诺生物登陆科创板 成为首个“A+H”疫苗股

8月13日，康希诺生物股份公司（以下简称“康希诺生物”）成功登陆科创板，成为首个“A+H”疫苗股。康希诺生物（康希诺688185.SH，康希诺生物06185.HK）此次科创板公开发行股票数量为2480万股，发行价格为209.71元。

募集资金将用于生产基地二期建设、在研疫苗研发、疫苗追溯、冷链物流体系及信息系统建设及补充流动资金。

康希诺生物董事长、首席执行官宇学峰博士表示：“上海证券交易所推出科创板及香港联交所上市制度改革，对于前期投入规模大、周期长，需要持续获得资金推进研发的生物医药企业，都是极为重要的政策支持，对于企业品牌价值的提升，及立足中国进行全球化战略布局具有积极意义。我们将一如既往地坚持以研发、生产和商业化高质量、创新及可负担的疫苗为己任，为中国乃至全球公共卫生水平的提升做出贡献。”

康希诺生物以在世界范围内提供预防传染病和感染病的解决方案为目标，专业从事高质量人用疫苗的研发、生产和商业化，在一大批疫苗领域的知名科学家和资深技术专家的带领下，建立了基于腺病毒载体疫苗技术、蛋白结构设计和重组技术、结合技术和制剂技术等四大核心技术平台，拥有多项疫苗核心知识产权及专有技术。

依托上述技术平台，康希诺生物开展针对脑膜炎、埃博拉病毒病、百白破、肺炎、结核病、新型冠状病毒（COVID-19）、带状疱疹等13个适应症研发16种重磅疫苗，并快速推进在研管线产品的开发。

其中，康希诺生物与军事科学院军事医学研究院生物工程研究所（以下简称“军科院生物工程研究所”）合作研发的重组埃博拉病毒病疫苗（腺病毒载体）已获得新药注册批准，是中国独立研发、具有完全自主知识产权的全球创新疫苗产品。两款在研脑膜炎球菌结合疫苗已临近商业化，国内首创的四价脑膜炎球菌结合疫苗已获得国家药品监督管理局新药注册优先审评资格。

2020年3月，康希诺生物与军科院生物工程研究所联合研发的重组新型冠状病毒疫苗（腺病毒载体）成为全球率先进入临床研究阶段的新冠候选疫苗，目前已完成二期临床试验，并获得中央军委后勤保障部卫生局颁发的军队特需药品批件，有效期一年，可在军队内部使用。

此外，康希诺生物的重组肺炎蛋白疫苗、13价肺炎球菌结合疫苗、婴幼儿组分百白破疫苗、结核病加强疫苗等多种创新疫苗处在临床试验阶段，另有六款候选疫苗处在临床前研究阶段。全面的疫苗管线将为后续的持续盈利能力提供坚实的保障,市场期待着康希诺生物对标国际质量标准的疫苗产品陆续问世，实现为中国及全球提供创新、优质、可及疫苗的使命。

关于康希诺生物

康希诺生物股份公司（H股简称：康希诺生物，代码06185.HK；A股简称：康希诺，代码688185.SH），2009年成立于中国天津，致力于为中国及全球公共卫生研发、生产和商业化创新疫苗。公司现有四个创新疫苗平台技术，包括腺病毒载体疫苗技术、结合技术、蛋白设计与重组技术、制剂技术。目前，公司已建立覆盖13种传染病的16种疫苗的强大研发管线，其中包括2017年获得批准的全球创新重组埃博拉病毒病疫苗以及目前在研的重组新型冠状病毒疫苗（腺病毒载体）。

FOR IMMEDIATE RELEASE

CanSinoBIO’s Successful Listing on STAR MarketMakes it the Initial Dual Listing Vaccine Company

SHANGHAI, CHINA, August 13, 2020,CanSino Biologics Inc. (“CanSinoBIO”) (SHSE: 688185, HKEX:06185) announced today that it has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+ H" dual listing vaccine company. CanSinoBIO will issue 24.8 million shares at the issue price of RMB209.71 per Share.

The funds will provide full support to the construction of the second phase manufacturing facility, vaccine research and development, vaccine traceability, the construction of cold chain logistics system and information system, as well as the supplementary working capital.

Dr. Xuefeng Yu, chairman and chief executive officer of CanSinoBIO, said: "The launch of STAR Market and the reform of HKEX listing have provided policy support for biopharmaceutical companies that require continuous long-term, large-scale investments for research and development of vaccine candidates. It allows companies to have branding benefits and make global strategic plans. We will continue being committed to making the innovative and affordable high-quality vaccines accessible to people and contributing to the improvement of public health worldwide."

With the goal of providing solutions to prevent infectious diseases globally, CanSinoBIO is dedicated to the research, development, manufacturing and commercialization of high-quality vaccines for human use. Led by a team of accomplished scientists and experienced experts in the field of vaccines, CanSinoBIO has developed four key platform technologies, including adenovirus-based viral vector vaccine, conjugation, protein structure design and recombination as well as vaccine formulation technologies. In addition, it has in-licensed a number of core intellectual properties.

CanSinoBIO is currently developing 16 vaccine candidates for 13 infectious disease areas, including meningitis, pneumonia, tuberculosis, COVID-19, Ebola virus disease, pertussis, diphtheria, tetanus, shingles etc.

Among them, the recombinant Ebola virus vaccine (Ad5-EBOV), jointly developed by CanSinoBIO and the Beijing Institute of Biotechnology, Academy of Military Medical Sciences (BIB), has obtained the approval in China. The two meningococcal conjugate vaccines under research are close to commercialization, among which the quadrivalent meningococcal conjugate vaccine is the first of its kind in China that has been granted priority review designation by the China National Medical Products Administration (NMPA).

In March 2020, the Recombinant Novel Coronavirus Vaccine (the “Ad5-nCoV”), a vaccine candidate co-developed by CanSinoBIO and BIB, became the world's initial vaccine candidate to enter the clinical research stage. The two phases of the clinical trial has now been completed and the results had already been published on the Lancet journal. In June, the vaccine received China’s military specially-needed drug approval with a valid period for one year.

In addition, the Pneumococcal vaccine portfolio, DTcP vaccine portfolio, TB Booster and several other innovative vaccines are currently under clinical trial stage or pre-clinical research stage. The comprehensive vaccine product pipeline will not only ensure the continuous profitability in the near future, but will also help realize the mission of providing innovative, high-quality and accessible vaccines for China and the world.

About CanSinoBIO

Incorporated in 2009, CanSinoBIO (SHSE: 688185, HKEX:06185) commits to research, production and commercialization of innovative vaccines for China and global public health security. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 16 vaccines preventing 13 diseases, including a globally innovative Ebola virus vaccine approved in 2017 as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector). Additional information can be found online at www.cansinotech.com